Mirabegron Structural Formula (Image 01)
Myrbetriq Tablet, Film Coated, Extended Release
Product Images NDC 0469-2602
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Myrbetriq (NDC 0469-2602). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Astellas Logo (Image 02)
Astellas Logo (Image 03)
Logo.jpg (Image 04)
Logo.jpg (Image 05)
25mg Extended Release Tablet Carton (Image 06)
Myrbetriq® (mirabegron extended-release tablets) is a medication taken once daily that comes in 25 mg tablets. The tablets should be swallowed whole and should not be crushed or chewed. This prescription medication is prescribed in 30-tablet quantities. All prescription medications, including Myrbetriq, should be kept out of reach of children.*
50mg Extended Release Tablet Carton (Image 07)
Figure 1 (Image 08)
The text describes a chart that shows the effect of inhibitors/inducers of CYP3A/Pgp on PK fold change and 90% confidence interval. The chart includes recommended dose adjustments for ketoconazole and rifampicin, with no changes needed for these medications. The chart also includes solifenacin, tamsulosin, and metformin, with no dose adjustments recommended for these medications either. There is a graph as well, displaying the mean change relative to mirabegron alone over time.*
Figure 2 (Image 09)
This text provides information on the recommended dose adjustments for various drugs that are metabolized by the enzymes CYP3A4 and CYP2D6. Solifenacin, ethinylestradiol, and levonorgestrel do not require any dose adjustment. Desipramine and metoprolol should be used with caution, while tamsulosin and metformin do not require any dose adjustment. Digoxin requires a starting dose adjustment, and for warfarin, the dosing should be guided by footnote 3. Information about the mean change relative to the substrate alone is also provided.*
Figure 3 (Image 10)
Figure 4 (Image 11)
Figure 5 (Image 12)
Figure 6 (Image 13)
Figure 7 (Image 14)
This appears to be a table showing mean changes from baseline for different treatment groups in a clinical trial related to a drug called "mirabegron" at different time points. The drug was tested at two different doses: 25 mg and 50 mg. The table shows data for three groups: a placebo group (n=262), a group receiving mirabegron 25mg (n=254), and a group receiving mirabegron 50mg (n=257). However, without more context it is difficult to interpret the table further.*
Figure 8 (Image 15)
This appears to be a table or graph displaying numerical data related to a study or clinical trial. It shows the mean change from baseline for participants receiving either a placebo or two doses of a drug called Mirabegron at 4, 8, and 12 weeks. However, without further context or explanation it is difficult to interpret the data or its significance.*
Figure 9 (Image 16)
Figure 10 (Image 17)
This text appears to be a chart depicting the adjusted change from baseline in some sort of study or experiment. The chart includes various measurements taken at different time periods (baseline, week 4, week 8, and week 12), and different dosages (25mg and 50mg). It's difficult to determine what exactly is being measured without more context, but it appears to be some sort of percent change in response to different treatments.*
Myrbetriq Granules Carton Image (Image 18)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
